Commonwealth Equity Services’s Pacira BioSciences PCRX Stock Holding History

Commonwealth Equity Services’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-2,793	Closed	-$213K	–	3767
2022 Q1	$213K	Sell	2,793 -2,261	-45%	-$151K	﹤0.01%	3279
2021 Q4	$304K	Buy	+5,054	New	+$279K	﹤0.01%	2960
2021 Q2	–	Sell	-3,229	Closed	-$226K	–	3560
2021 Q1	$226K	Sell	3,229 -150	-4%	-$10.7K	﹤0.01%	3030
2020 Q4	$202K	Buy	+3,379	New	+$198K	﹤0.01%	2916
2016 Q1	–	Sell	-3,223	Closed	-$247K	–	2250
2015 Q4	$247K	Buy	+3,223	New	+$183K	﹤0.01%	1742
2015 Q3	–	Sell	-3,640	Closed	-$257K	–	2205
2015 Q2	$257K	Buy	3,640 +956	+36%	+$75.3K	﹤0.01%	1744
2015 Q1	$238K	Buy	2,684 +245	+10%	+$24.9K	﹤0.01%	1785
2014 Q4	$216K	Hold	2,439	–	–	﹤0.01%	1798
2014 Q3	$236K	Buy	2,439 +9	+0.4%	+$876	﹤0.01%	1721
2014 Q2	$223K	Buy	+2,430	New	+$185K	﹤0.01%	1751

Other funds holding PCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SCM

Spyglass Capital Management San Francisco, California $1.85B AUM 15.7% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Commonwealth Equity Services's PCRX Position: Q2 2022 in Review

Commonwealth Equity Services sold out of Pacira BioSciences (PCRX) in Q2 2022, closing a stake of 2,793 shares — an estimated $213K sold.

Commonwealth Equity Services first reported a position in PCRX in Q2 2014 and held it in 10 quarters. The position peaked at $304K in Q4 2021. 284 funds tracked by Wall St. Rank hold PCRX as of Q2 2022.

Commonwealth Equity Services reported no remaining Pacira BioSciences position as of Q2 2022 after selling out during the quarter.
Commonwealth Equity Services sold 2,793 Pacira BioSciences shares in Q2 2022, an estimated $213K.
Commonwealth Equity Services first reported a position in Pacira BioSciences in Q2 2014 and held it in 10 quarters.
Commonwealth Equity Services's Pacira BioSciences position peaked at $304K in Q4 2021.
284 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2022.

Based on Commonwealth Equity Services's 13F filing for Q2 2022, filed 19 Jul 2022.